SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
SCYNEXIS (SCYX) will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston on November 9-11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SCYNEXIS (SCYX) will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston on November 9-11, 2026.
Senior leadership will hold one-on-one meetings November 9-10 and a fireside chat November 9 from 2:30 p.m. to 3:00 p.m. ET. A live webcast of the chat will be available, with a replay on the company website for 90 days following the event.
Details
Market Reaction – SCYX
On Oct 29, the day this news came out, the latest delayed price for SCYX is 3.04% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $3.83. Relative volume is elevated at 2.1x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.
One-on-One Meetings
Dates: November 9-10, 2026
Fireside Chat
Date: Monday, November 9, 2026
Time: 2:30 p.m.-3:00 p.m. ET
A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com
